Novartis Secures Pair of Regulatory Wins for Skin Disease and Malaria Treatments

Why It Matters

The oral CSU therapy could reshape a market dominated by costly injectables, while the WHO prequalification expands life‑saving malaria treatment to the most vulnerable newborns, reinforcing Novartis’s dual focus on commercial growth and global health impact.

Key Takeaways

• Rhapsido approved in EU, first oral chronic spontaneous urticaria therapy
• Forecasted $2.6 bn global sales for Rhapsido by 2032
• WHO prequalifies Coartem Baby for infants 2‑5 kg, enabling public‑sector procurement
• Novartis to supply Coartem Baby mainly on not‑for‑profit basis
• Rhapsido trials assess multiple sclerosis, chronic inducible urticaria, food allergy

Pulse Analysis

Novartis’s European approval of Rhapsido marks a watershed moment for chronic spontaneous urticaria (CSU) treatment. Until now, patients relied on injectable biologics such as Dupixent and Xolair, which command premium pricing and require clinic visits. An oral BTK inhibitor that can be taken twice daily simplifies adherence and reduces monitoring costs, potentially accelerating market penetration. Analysts forecast $2.6 billion in global revenue by 2032, suggesting that the convenience factor may shift prescribing habits toward Novartis’s pill, especially in health systems seeking cost‑effective alternatives.

The WHO’s prequalification of Coartem Baby extends the reach of artemisinin‑based combination therapy to infants as light as two kilograms, a demographic previously underserved by standard formulations. By meeting stringent safety and efficacy criteria, the product becomes eligible for United Nations‑backed procurement, enabling ministries of health in malaria‑endemic regions to purchase at scale. Novartis’s commitment to supply the drug on a not‑for‑profit basis underscores a strategic blend of commercial stewardship and humanitarian responsibility, aligning with global‑health goals to reduce under‑five malaria mortality.

Together, these regulatory wins illustrate Novartis’s broader strategy of diversifying its portfolio while reinforcing its global‑health credentials. The company’s recent $2 billion acquisition of Excellergy, a biotech focused on next‑generation anti‑IgE therapies, signals an appetite for innovative biologics that complement its oral small‑molecule pipeline. Coupled with over $500 million invested in malaria R&D since 2021, Novartis is positioning itself at the intersection of high‑margin specialty drugs and essential medicines, a balance that could drive sustainable growth amid evolving payer pressures.